Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis comparison between methotrexate and cyclosporine

Sarah Law Ping Man (1) , Guillaume Bouzillé (2, 3, 4) , Nathalie Beneton (5) , Gilles Safa (6) , Alain Dupuy (7, 1) , Catherine Droitcourt (3, 7, 1)

1 Service de Dermatologie [Rennes] = Dermatology [Rennes]
2 LTSI - Laboratoire Traitement du Signal et de l'Image
3 CIC - Centre d'Investigation Clinique [Rennes]
4 Clinical Data Center [CHU Rennes]
5 Service de dermatologie [CH Le Mans]
6 CHU de Saint-Brieuc
7 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins

Introduction Cyclosporine and methotrexate are the two preferred first-line immunosuppressive treatments in atopic dermatitis. The aim of this study was to compare the treatment profiles of methotrexate and cyclosporine in daily practice as the first-line immunosuppressive treatment in atopic dermatitis, using two survival analyses, ‘drug survival’ (time on the drug) and ‘postdrug survival’ (time between two drugs). Methods Retrospective study including patients with moderate-to-severe atopic dermatitis treated with methotrexate or cyclosporine as the first-line immunosuppressive treatment. The reasons for discontinuation of treatment were collected as follows: controlled disease, treatment failure, side event pregnancy and non-compliance. ‘Drug survival’ and ‘postdrug survival’ analyses were performed using the Kaplan–Meier method and predictive factors were analysed using uni- and multivariate Cox regression analyses. Results Fifty-six patients, among whom 25 patients treated with cyclosporine and 31 with methotrexate (median age: 34 ± 15 years), were included between 2007 and 2016. Reasons for discontinuation were not significantly different between ‘controlled disease’ and other reasons (P = 0.11). The median ‘drug survival’ was significantly longer for methotrexate (23 months) than for cyclosporine (8 months) (P < 0.0001). Six months from baseline, 93% of patients treated with methotrexate were still being treated vs 63% among patients treated with cyclosporine. The median of ‘postdrug survival’ was significantly longer for methotrexate (12 months) than for cyclosporine (2 months). Only treatment with CYC was a predictive factor for decreased ‘drug survival’ and ‘postdrug survival’. Conclusion This is the first direct comparison between methotrexate and cyclosporine as first-line immunosuppressive treatments for moderate-to-severe atopic dermatitis in daily practice. We evidenced two different treatment profiles: the duration of methotrexate administration is longer than that of cyclosporine. ‘Postdrug survival’ could be a new tool to assess the maintenance of effect of a drug after withdrawal in atopic dermatitis, and more broadly in chronic skin disease.

Keywords: immunosuppressive treatment; atopic dermatitis; post-drug survival; drug survival

Domains: Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology; Life Sciences [q-bio]; Immunology; Immunotherapy; Life Sciences [q-bio]; Human health and pathology; Dermatology

Sarah Law Ping Man, Guillaume Bouzillé, Nathalie Beneton, Gilles Safa, Alain Dupuy, et al.. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis comparison between methotrexate and cyclosporine. Journal of the European Academy of Dermatology and Venereology, 2018, 32 (8), pp.1327-1335. ⟨10.1111/jdv.14880⟩. ⟨hal-01798651⟩